Serum Free Light Chain (sFLC) Assays Market Size Analysis and Long Term Growth Prospects 2034
Serum Free Light Chain (sFLC) Assays Market Size Analysis and Long Term Growth Prospects 2034
The Serum Free Light Chain (sFLC) assays market size in 2026 are diagnostic tests used to detect, diagnose, and monitor plasma cell disorders, including multiple myeloma, primary amyloidosis, and related diseases. These assays measure the levels of free kappa and lambda light chains in blood and human serum and can support the monitoring of disease progression and treatment response. The growing need for sensitive quantitative diagnostic tests is supporting the adoption of sFLC assays across hospitals, clinical laboratories, and pathology laboratories.
According to Fortune Business Insights, the global serum free light chain (sFLC) assays market size was valued at USD 266.13 million in 2025 and is projected to grow from USD 288.43 million in 2026 to USD 569.1 million by 2034, exhibiting a CAGR of 8.87% during the forecast period. North America dominated the serum free light chain (sFLC) assays market with a market share of 49.63% in 2025. The increasing prevalence of multiple myeloma, demand for highly sensitive diagnostic tests, product approvals, technological developments, and expansion initiatives by market participants are supporting market growth.
Serum Free Light Chain assays provide quantitative measurement of free light chains and are used in the diagnosis, prognosis, and monitoring of plasma cell disorders. According to Fortune Business Insights, these assays are increasingly important because conventional laboratory methods may have limitations in detecting and quantifying free light chains, particularly in certain cases of multiple myeloma, light chain amyloidosis, and related disorders. The growing awareness of chronic disorders and the increasing need for early and accurate disease assessment are contributing to the adoption of these diagnostic solutions. The market is also benefiting from technological advancements in immunoassay systems, automated diagnostic platforms, and quantitative testing technologies.
The rising prevalence of multiple myeloma is one of the major factors driving demand for serum free light chain assays. Factors associated with the condition include increasing age, family history, radiation exposure, and other plasma cell disorders. The growing patient population is increasing the demand for diagnostic laboratory testing, including serum protein electrophoresis, immunofixation electrophoresis, and sFLC assays.
The high sensitivity of serum free light chain assays and their ability to support disease progression monitoring are encouraging their adoption. Fortune Business Insights highlights that these tests can provide benefits for the follow-up and monitoring of patients with low levels of monoclonal proteins.
Advancements in diagnostic assay technology and increasing adoption of automated systems are supporting market development. Market participants are also focusing on research and development involving artificial intelligence and machine learning to improve diagnostic products and quantitative testing.
Limitations associated with serum free light chain quantification may restrict market expansion. Antigen excess, variations in free light chain characteristics, and differences in reagents and instruments can affect test results. The influence of kidney function on free light chain concentrations may also create challenges in interpreting results among patients with chronic kidney disease.
The serum free light chain (sFLC) assays market is highly consolidated, with a limited number of prominent companies operating globally. Thermo Fisher Scientific Inc., Sebia, Siemens Healthineers AG, and Diazyme Laboratories, Inc. are among the key companies profiled in the market.
Thermo Fisher Scientific Inc. held the highest market share in 2024, supported by its geographical presence and adoption of the Freelite assay across different regions. The company has also undertaken initiatives involving new products and geographical expansion. In January 2023, Thermo Fisher Scientific Inc. completed the acquisition of The Binding Site for USD 2.8 billion, expanding its specialty diagnostics portfolio related to multiple myeloma.
Sebia has also maintained a significant market presence through geographical expansion and strategic initiatives. Other companies, including Siemens Healthineers AG and Diazyme Laboratories, Inc., are expected to maintain their presence through collaborations, partnerships, product development, and other strategic activities.
Thermo Fisher Scientific Inc. (U.S.)
Siemens Healthineers AG (Germany)
Sebia (France)
Diazyme Laboratories, Inc. (U.S.)
By Technique (Latex Nephelometric, Latex Turbidometric, ELISA, and Lateral Flow Immunoassay)
By Indication (Multiple Myeloma, Light Chain Amyloidosis, and Others)
By End-user (Hospital Laboratories, Clinical & Pathology Laboratories, and Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/serum-free-light-chain-assays-sflc-market-102087
North America accounted for USD 132.07 million in 2025 and is projected to reach USD 142.81 million in 2026. The region held a 49.63% share of the global market in 2025. Increasing adoption of serum free light chain tests, product launches, and approvals for additional disease indications are supporting regional growth.
Europe reached USD 89.6 million in 2025 and is expected to grow to USD 97.34 million in 2026. The region benefits from the strong presence of major companies, extensive distribution networks, rising multiple myeloma incidence, and clinical studies focused on novel products.
Asia Pacific stood at USD 29.37 million in 2025 and is projected to reach USD 31.99 million in 2026. Increasing awareness regarding early diagnosis of plasma cell disorders and initiatives by major companies to expand their product presence in developing economies are supporting regional demand.
The future scope of the serum free light chain (sFLC) assays market is supported by increasing R&D activities, overseas expansion, technological advancements, and growing applications in personalized medicine. Market participants are focusing on expanding diagnostic product portfolios across developed and emerging countries. Investments in artificial intelligence and machine learning are also expected to support the development of advanced diagnostic products and improve quantitative testing.
Curious About Japan’s Market? Explore the Latest -Serum Free Light Chain Assays Market- Insights